George Church is bullish on gene therapy for aging. We target rare diseases, so by economies of scale, prices remain high. But aging is the most common disease. Once we scale viral-vector factories like mRNA vaccine plants, per-dose costs could drop below a domestic flight.

Had an amazing time this past week DeSci.Berlin talking about the bottlenecks in biotech innovation with Hannah Payette Peterson, Dr. Kai Bindseil, and chris lewis, and how to unlock new pathways for funding. Thanks to Molecule & Bio Protocol - let's get more moonshot ideas through the VoD!